RESILIENT Part 1: Phase II Study of Liposomal Irinotecan After Platinum Chemotherapy in Small-Cell Lung Cancer

May 29-31, 2020; Online at meetings.asco.org/am
Patients who were platinum sensitive during first-line platinum therapy more likely to respond to second-line liposomal irinotecan than those who were platinum resistant.
Format: Microsoft PowerPoint (.ppt)
File Size: 233 KB
Released: June 3, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Related Content

Downloadable slides highlighting strategies for assessing and using biomarkers to guide treatment for patients with NSCLC, by Clinical Care Options.

Matthew Gubens, MD, MS Lauren L. Ritterhouse, MD Released: May 7, 2021

Video of expert discussion of emerging antibody-drug conjugates targeting HER2, HER3, and TROP2 for lung cancers from Clinical Care Options (CCO)

Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Program Director
person default Conor Ernst Steuer, MD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits ABIM MOC: maximum of 0.25 Medical Knowledge MOC point(s) Released: May 7, 2021 Expired: May 6, 2022

Downloadable slides highlighting strategies in using biomarkers to guide treatment decisions for patients with NSCLC, by Clinical Care Options.

Matthew Gubens, MD, MS Released: April 27, 2021

Downloadable slides highlighting best approaches for detecting biomarkers to guide treatment decisions in NSCLC, by Clinical Care Options.

Lauren L. Ritterhouse, MD Released: April 27, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue